DK1944040T3 - Analysefremgangsmåde for Alzheimers sygdom - Google Patents
Analysefremgangsmåde for Alzheimers sygdomInfo
- Publication number
- DK1944040T3 DK1944040T3 DK07024341.5T DK07024341T DK1944040T3 DK 1944040 T3 DK1944040 T3 DK 1944040T3 DK 07024341 T DK07024341 T DK 07024341T DK 1944040 T3 DK1944040 T3 DK 1944040T3
- Authority
- DK
- Denmark
- Prior art keywords
- alzheimer
- disease
- analysis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31322101P | 2001-08-17 | 2001-08-17 | |
| US33498701P | 2001-10-23 | 2001-10-23 | |
| EP02766022A EP1416965B8 (en) | 2001-08-17 | 2002-08-16 | Assay method for alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1944040T3 true DK1944040T3 (da) | 2012-10-29 |
Family
ID=39294145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07024341.5T DK1944040T3 (da) | 2001-08-17 | 2002-08-16 | Analysefremgangsmåde for Alzheimers sygdom |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US7771722B2 (da) |
| EP (1) | EP1944040B1 (da) |
| AU (2) | AU2002329775C1 (da) |
| CY (1) | CY1113143T1 (da) |
| DK (1) | DK1944040T3 (da) |
| ES (1) | ES2391905T3 (da) |
| PT (1) | PT1944040E (da) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003015691A2 (en) * | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | RAPID IMPROVEMENT OF COGNITION IN CONDITIONS RELATED TO A$g(b) |
| DK1944040T3 (da) * | 2001-08-17 | 2012-10-29 | Univ Washington | Analysefremgangsmåde for Alzheimers sygdom |
| WO2003016466A2 (en) * | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | ANTI-Aβ ANTIBODIES |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| WO2004071408A2 (en) * | 2003-02-10 | 2004-08-26 | Applied Molecular Evolution, Inc. | Aβ BINDING MOLECULES |
| WO2005120571A2 (en) * | 2004-06-07 | 2005-12-22 | Ramot At Tel Aviv University Ltd. | Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation |
| WO2006110621A2 (en) * | 2005-04-11 | 2006-10-19 | Cornell Research Foundation, Inc. | Multiplexed biomarkers for monitoring the alzheimer's disease state of a subject |
| US8741260B2 (en) * | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
| BRPI0619249A2 (pt) | 2005-11-30 | 2011-09-20 | Abbott Lab | anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos |
| CN101506236B (zh) | 2005-11-30 | 2012-12-12 | 雅培制药有限公司 | 抗淀粉样β蛋白的单克隆抗体及其用途 |
| RU2015111675A (ru) | 2005-12-12 | 2015-08-10 | Ац Иммуне Са | Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами |
| PE20100684A1 (es) * | 2005-12-12 | 2010-10-04 | Hoffmann La Roche | Anticuerpo anti b-4-amiloide que contiene asparagina glicosilada en la region variable de vh |
| AR062065A1 (es) | 2006-07-14 | 2008-10-15 | Ac Immune Sa | Anticuerpo humanizado |
| CA2661042C (en) | 2006-08-18 | 2012-12-11 | Armagen Technologies, Inc. | Agents for blood-brain barrier delivery |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| CN103408661B (zh) * | 2007-01-05 | 2016-04-06 | 苏黎世大学 | 提供疾患特异性结合分子和靶的方法 |
| IL199534A (en) | 2007-01-05 | 2013-01-31 | Univ Zuerich | An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses. |
| LT2842967T (lt) * | 2007-01-18 | 2017-02-27 | Eli Lilly And Company | Beta amiloido pegilintas fab |
| EP2486928A1 (en) | 2007-02-27 | 2012-08-15 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
| US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| US8613923B2 (en) * | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| MX2009013505A (es) * | 2007-06-12 | 2010-01-27 | Ac Immune Sa | Anticuerpos humanizados para amiloide beta. |
| JP5901877B2 (ja) * | 2007-07-27 | 2016-04-13 | アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． | 中枢神経系のα−Ｌ−イデュロニダーゼ活性を増加させるための方法および組成物 |
| CN101883790B (zh) | 2007-10-05 | 2015-09-09 | 基因技术公司 | 抗淀粉样蛋白β抗体在眼病中的用途 |
| AU2008311365B2 (en) * | 2007-10-05 | 2015-03-12 | Ac Immune S.A. | Humanized antibody |
| PL2949666T3 (pl) | 2008-12-19 | 2019-07-31 | Biogen International Neuroscience Gmbh | Ludzkie przeciwciała przeciwko alfa-synukleinie |
| JP5873003B2 (ja) | 2009-03-18 | 2016-03-01 | アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． | ＩｇＧデコイ受容体融合タンパク質の血液脳関門送達のための組成物および方法 |
| WO2011044542A1 (en) | 2009-10-09 | 2011-04-14 | Armagen Technologies, Inc. | Methods and compositions for increasing iduronate 2-sulfatase activity in the cns |
| MX360403B (es) | 2010-04-15 | 2018-10-31 | Abbvie Inc | Proteinas de union a amiloide beta. |
| RU2607368C2 (ru) | 2010-07-30 | 2017-01-10 | Ац Иммуне С.А. | Безопасные и функциональные гуманизированные антитела |
| JP6147665B2 (ja) | 2010-08-14 | 2017-06-14 | アッヴィ・インコーポレイテッド | アミロイドベータ結合タンパク質 |
| EP2511296A1 (en) | 2011-04-12 | 2012-10-17 | Araclón Biotech, S. L. | Antibody, kit and method for determination of amyloid peptides |
| SI2723379T1 (sl) | 2011-06-23 | 2019-03-29 | Biogen International Neuroscience Gmbh | Molekule, ki se vežejo ma anti alfa-sinuklein |
| EP2785378B1 (en) | 2011-12-02 | 2020-05-13 | Armagen, Inc. | Methods and compositions for increasing arylsulfatase a activity in the cns |
| US10830775B2 (en) | 2014-09-30 | 2020-11-10 | Washington University | Tau kinetic measurements |
| MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| EP3034214A1 (en) * | 2014-12-19 | 2016-06-22 | Pramet Tools, S.R.O. | Drill and drill insert with chipbreaker protrusions |
| US10538589B2 (en) | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
| HRP20220304T1 (hr) | 2015-06-24 | 2022-05-13 | F. Hoffmann - La Roche Ag | Anti-transferinska receptorska protutijela s prilagođenim afinitetom |
| PE20181004A1 (es) | 2015-10-02 | 2018-06-26 | Hoffmann La Roche | Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso |
| AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
| EA202090555A1 (ru) | 2017-08-22 | 2020-06-08 | Байоджен Ма Инк. | Фармацевтические композиции, содержащие антитела к бета-амилоиду |
| TW202243690A (zh) | 2021-01-11 | 2022-11-16 | 美商美國禮來大藥廠 | 抗N3pGlu類澱粉β抗體及其用途 |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
| WO2023150483A1 (en) | 2022-02-03 | 2023-08-10 | Eli Lilly And Company | Regional tau imaging for diagnosing and treating alzheimer's disease |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5278049A (en) * | 1986-06-03 | 1994-01-11 | Incyte Pharmaceuticals, Inc. | Recombinant molecule encoding human protease nexin |
| FR2608669A1 (fr) | 1986-12-19 | 1988-06-24 | Boussois Sa | Vitrage pret a sa pose et son procede de fabrication et de fixation |
| US4933156A (en) * | 1987-04-08 | 1990-06-12 | Salutar, Inc. | Amyloidosis and Alzheimer's disease diagnostic assay and reagents therefor |
| US5004697A (en) * | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5753624A (en) * | 1990-04-27 | 1998-05-19 | Milkhaus Laboratory, Inc. | Materials and methods for treatment of plaquing disease |
| US5837822A (en) * | 1992-01-27 | 1998-11-17 | Icos Corporation | Humanized antibodies specific for ICAM related protein |
| US5837672A (en) | 1992-07-10 | 1998-11-17 | Athena Neurosciences, Inc. | Methods and compositions for the detection of soluble β-amyloid peptide |
| US5766846A (en) * | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
| CA2115900A1 (en) | 1993-02-22 | 1994-08-23 | Gerald W. Becker | Pharmaceutical screens and antibodies |
| AU692237B2 (en) | 1994-02-03 | 1998-06-04 | Picower Institute For Medical Research, The | Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis |
| US5688651A (en) | 1994-12-16 | 1997-11-18 | Ramot University Authority For Applied Research And Development Ltd. | Prevention of protein aggregation |
| US5786180A (en) | 1995-02-14 | 1998-07-28 | Bayer Corporation | Monoclonal antibody 369.2B specific for β A4 peptide |
| US6037454A (en) * | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
| US6218506B1 (en) * | 1997-02-05 | 2001-04-17 | Northwestern University | Amyloid β protein (globular assembly and uses thereof) |
| US20020086847A1 (en) * | 1997-04-09 | 2002-07-04 | Mindset Biopharmaceuticals (Usa) | Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof |
| EP2305709A1 (en) | 1997-04-09 | 2011-04-06 | Intellect Neurosciences, Inc. | Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods for use thereof |
| US6787319B2 (en) * | 1997-04-16 | 2004-09-07 | American Home Products Corp. | β-amyloid peptide-binding proteins and polynucleotides encoding the same |
| IT1293511B1 (it) | 1997-07-30 | 1999-03-01 | Gentili Ist Spa | Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati |
| JP2001512689A (ja) * | 1997-08-11 | 2001-08-28 | カイロン コーポレイション | Ｔ細胞を遺伝子改変するための方法 |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| DK1078005T3 (da) | 1998-05-21 | 2010-08-09 | Univ Tennessee Res Foundation | Fremgangsmåder til amyloidfjernelse ved anvendelse af anti-amyloidantistoffer |
| UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
| WO2000077178A1 (en) * | 1999-06-16 | 2000-12-21 | Boston Biomedical Research Institute | IMMUNOLOGICAL CONTROL OF β-AMYLOID LEVELS IN VIVO |
| CA2381323C (en) | 1999-08-04 | 2009-10-06 | University Of Southern California | Amyloid .beta. protein (globular assembly and uses thereof) |
| CA2349434A1 (en) | 1999-09-03 | 2001-03-15 | Ramot University Authority For Applied Research & Industrial Development Ltd. | Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases |
| US6294171B2 (en) | 1999-09-14 | 2001-09-25 | Milkhaus Laboratory, Inc. | Methods for treating disease states comprising administration of low levels of antibodies |
| AU2610901A (en) | 1999-12-30 | 2001-07-16 | Washington University | Predictive diagnostic for alzheimer's disease |
| CN101670105B (zh) * | 2000-02-24 | 2014-08-06 | 华盛顿大学 | 螯合淀粉样蛋白β肽的人源化抗体 |
| US20020009445A1 (en) * | 2000-07-12 | 2002-01-24 | Yansheng Du | Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease |
| DE60139788D1 (de) | 2000-09-06 | 2009-10-15 | Aventis Pharma Sa | Verfahren und zusammensetzungen für amyloidosis-verbundene krankheiten |
| PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| EP1221680A1 (de) | 2001-01-09 | 2002-07-10 | Häni- Prolectron AG | Verfahren zur Verrechnung einer Leistung durch Erfassung eines Billetts |
| WO2003016466A2 (en) * | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | ANTI-Aβ ANTIBODIES |
| DK1944040T3 (da) * | 2001-08-17 | 2012-10-29 | Univ Washington | Analysefremgangsmåde for Alzheimers sygdom |
| DE60224200T2 (de) | 2001-08-17 | 2008-07-10 | Eli Lilly And Co., Indianapolis | Assayverfahren für alzheimer-krankheit |
-
2002
- 2002-08-16 DK DK07024341.5T patent/DK1944040T3/da active
- 2002-08-16 AU AU2002329775A patent/AU2002329775C1/en not_active Ceased
- 2002-08-16 PT PT07024341T patent/PT1944040E/pt unknown
- 2002-08-16 US US10/486,908 patent/US7771722B2/en active Active
- 2002-08-16 EP EP07024341A patent/EP1944040B1/en not_active Expired - Lifetime
- 2002-08-16 ES ES07024341T patent/ES2391905T3/es not_active Expired - Lifetime
-
2008
- 2008-06-30 AU AU2008202875A patent/AU2008202875B2/en not_active Ceased
-
2010
- 2010-07-12 US US12/834,271 patent/US8444977B2/en not_active Expired - Lifetime
-
2012
- 2012-09-19 CY CY20121100857T patent/CY1113143T1/el unknown
-
2013
- 2013-04-16 US US13/863,629 patent/US9453069B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US9453069B2 (en) | 2016-09-27 |
| EP1944040A3 (en) | 2008-12-24 |
| US20100279433A1 (en) | 2010-11-04 |
| PT1944040E (pt) | 2012-10-31 |
| AU2002329775C1 (en) | 2011-04-07 |
| AU2008202875A1 (en) | 2008-07-24 |
| AU2008202875B2 (en) | 2010-11-11 |
| US7771722B2 (en) | 2010-08-10 |
| US20040248197A1 (en) | 2004-12-09 |
| ES2391905T3 (es) | 2012-11-30 |
| AU2002329775B2 (en) | 2008-04-03 |
| US20130230513A1 (en) | 2013-09-05 |
| CY1113143T1 (el) | 2016-04-13 |
| EP1944040B1 (en) | 2012-08-01 |
| EP1944040A2 (en) | 2008-07-16 |
| US8444977B2 (en) | 2013-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1944040T3 (da) | Analysefremgangsmåde for Alzheimers sygdom | |
| NO20026199D0 (no) | Forbindelser for behandling av Alzheimers sykdom | |
| DK2211183T3 (da) | Fremgangsmåde til diagnosticering og overvågning af Alzheimer's sygdom | |
| DK1303272T3 (da) | Benzothiazolderivater til behandling af Alzheimers sygdom og Parkinsons sygdom | |
| EP1399582A4 (en) | METHOD FOR DETECTING A KIDNEY DISEASE BY PROTEIN PROFILING | |
| NO20052220D0 (no) | Fremgangsmater for behandling av Alzheimers sykdom ved anvendelse av antistoffer rettet mot amyloid beta-peptid og preparater derav | |
| NO20035010L (no) | Fremgangsmåter og blandinger for analysering av proteiner | |
| IS6316A (is) | Aðferð til erfðafræðilegra greininga | |
| DK1392287T3 (da) | Anvendelse af substituerede azetidinonderivater i behandlingen af Alzheimers sygdom | |
| NO20032007L (no) | Radiofarmasöytika for diagnostisering av Alzheimers sykdom | |
| ITMI20010985A0 (it) | Farmaci per il morbo di alzheimer | |
| DK2172208T3 (da) | Små peptider til behandling af alzheimers sygdom og andre beta-amyloidprotein- fibrillogeneseforstyrrelser | |
| AU2001273661A1 (en) | Methods of screening for alzheimer's disease | |
| IS7163A (is) | Aðferðir til meðhöndlunar á lungnasjúkdómi | |
| DK1456404T3 (da) | Fremgangsmåde til at bestemme difibrotids biologiske aktivitet | |
| AU2002336843A8 (en) | Biopolymer markers predictive of alzheimers disease | |
| ZA200603178B (en) | Quick test for the diagnosis of Alzheimer's disease | |
| DE60231875D1 (de) | Kartographisches bildsyntheseverfahren | |
| AUPR202400A0 (en) | Method of screening for inhibitors of alzheimer's disease | |
| AU2003251962A8 (en) | Screening for alzheimer's disease | |
| EP1832877A4 (en) | METHOD FOR THE STUDY OF MORBUS ALZHEIMER | |
| EP1693671A4 (en) | METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE | |
| FR2856409B1 (fr) | Methodes de detection de la maladie d'alzheimer | |
| FR2826454B1 (fr) | Cartes d'analyse | |
| ITMI20031709A1 (it) | Metodo per l'individuazione precoce della malattia di alzheimer. |